Articles tagged with Leukemia
A global clinical trial has shown a significant improvement in disease-free survival rates for children with B-cell acute lymphoblastic leukemia (B-ALL) by combining standard chemotherapy with blinatumomab, an immunotherapy. The study found improved survival rates of up to 97.5% after three years, compared to 90% with chemotherapy alone.
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
Marina Konopleva joins the Eradicating MRD in AML TeamLab to develop new ways to detect and target Minimal Residual Disease. MECCC has developed multiple targeted agents that have become standard of care for older AML patients, and will partner with Break Through Cancer to deepen understanding of MRD drivers.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
Researchers discover a molecular mechanism controlling PAX5, key regulator of B-cell maturation. Increasing SIRT7 activity may boost PAX5 levels in leukemic cells, inducing cell death.
A study of over 700 US counties found a link between childhood leukemia and radon gas levels, including those below the EPA's recommended mitigation threshold. Radon exposure increases the likelihood of leukemia in both boys and girls, according to the research.
A study found that children with Down's syndrome have an elevated number of red blood cells, which increases their risk of developing leukemia. The extra chromosome 21 alters DNA packing and gene regulation, contributing to the development of leukemia.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers found that approximately 60% of genetic changes driving T-ALL cancer cells are non-coding changes, significantly altering the understanding of disease biology. This leads to innovative treatments, including new immunotherapies developed at CHOP and St. Jude.
Researchers discovered novel genetic variations that influence relapse risk in children with standard-risk B-cell acute lymphoblastic leukemia (SR B-ALL). The study highlights the importance of genomic profiling in accurately determining patient risk and tailoring treatment intensity.
Scientists at St. Jude Children's Research Hospital identified age-related differences in B-ALL treatment outcomes, with children being more sensitive to certain drugs. The study suggests that both age and individual genomics must be considered to predict treatment response, leading to the need for tailored treatment strategies.
Infant leukemia with MLL gene rearrangements is resistant to glucocorticoids due to the production of NG2 protein. This leads to FLT3 activation and inactivation of the glucocorticoid receptor, rendering cells insensitive to treatment. The study provides new targets for drug development and immunotherapy.
Researchers found that type II innate lymphoid cells transform after a cancer patient receives stem cells from a donor, preventing an effective immune system rebuilding. This new understanding may lead to better strategies for enhancing immune system recovery post-transplantation.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
A team of researchers from Penn State College of Medicine identified KDR, a tyrosine kinase, as a potential drug target for treating diseases caused by human T-cell leukemia virus type 1 (HTLV-1). By blocking KDR, the viral protein Tax is degraded, leading to cell death and disruption of cancer-causing signaling pathways.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Patients with CLL and NHL who received frequent immunoglobulin G tests had fewer infections, required fewer antimicrobial medications, and higher blood levels of IgG. Increased IgG testing is associated with a lower risk of severe infections, suggesting that clear clinician guidance may save lives.
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
Researchers discovered that T-cell aging is not limited by organismal age, and healthy T cells can proliferate indefinitely. The epigenetic clock of T cells shows that death is not the end, and these cells do not plateau with age, defying traditional notions of cellular aging.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
A new study reveals that a type of childhood leukemia has its roots in fetal development, with chromosomal alterations detected in umbilical cord blood. The findings have important implications for understanding the disease and developing new therapies.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers have developed an approach to 'delete' a diseased blood system while building up a new, healthy one with donor blood stem cells. This process involves targeting specific antibodies coupled to a cytotoxic drug that recognize and destroy diseased blood cells while sparing healthy ones.
A novel andrographolide derivative (AND7) combined with TRAIL enhances anti-cancer effects and improves resistance. The AND7/TRAIL combination promotes apoptosis via P53 and ROS expression.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
Researchers at St. Jude Children's Research Hospital designed a combination therapy to effectively treat relapsed or resistant B-cell leukemia by targeting the developmental stages of cancer cells. The findings revealed that a protein called BCL-2 is a hidden vulnerability in asparaginase-resistant tumor cells.
Researchers found that discontinuing specialist follow-up care for patients with slow-growing CLL had no negative impact on survival, hospital visits or infections. Most patients who ended follow-up developed minor infections treated with antibiotics.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
A study from USC Keck School of Medicine reveals a genetic variant on the IKZF1 gene contributing to increased risk of acute lymphoblastic leukemia among Hispanic/Latino children. The variant increases ALL risk by around 1.4 times and may be linked to Indigenous American ancestry, according to researchers.
A large cohort study found that longer durations of exclusive breastfeeding were associated with a lower risk of childhood B-cell precursor-acute lymphoblastic leukemia. The study's results suggest potential biologic mechanisms underlying this association and inform the need for further research on preemptive interventions.
A genetic variant reducing IKZF1 expression increases B-cell ALL risk in Hispanic/Latino kids, with ancient DNA tracing its emergence ~13,000 years ago from Indigenous American ancestors.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A study by IRB Barcelona and Sant Joan de Déu Hospital reveals three distinct patterns explaining the occurrence of second cancers in children, including a mutational footprint from chemotherapy. The research advances understanding of pediatric cancer and highlights the importance of clinical data sharing.
A study by Dr Manel Esteller and colleagues identified an epigenetic signature associated with a good clinical response to hypomethylating drugs, enabling early detection of resistant patients. The research found single genes that facilitate the development of biomarkers and rescue strategies for non-responder patients.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
Researchers at City of Hope have developed a new approach to target and destroy hard-to-kill leukemia stem cells. The therapy method uses Type II interferon to disrupt the cancer cells' ability to divide, and a T cell engager antibody to create a bridge between the immune system and the leukemia stem cells.
Researchers identified mechanisms that cause ponatinib to harm the heart and found a promising treatment that could reverse this process. The treatment protects heart cells without diminishing the tumor-fighting efficacy of the drug.
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
Researchers discovered that combining fludarabine, melphalan, and low-dose total-body irradiation offers the best survival rate and lowest relapse rate in cord blood transplantation for myeloid malignancies. The study analyzed data from 1395 cases and found fewer deaths from infection with this combination.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...
A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.
The study found that dasatinib and blinatumomab combination treatment resulted in excellent median overall survival and disease-free survival times for patients 65 and older with Philadelphia chromosome-positive acute lymphoblastic leukemia. The regimen confirmed benefits of this treatment are durable, with a median overall survival of...
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.
Scientists at St. Jude Children's Research Hospital identified genes directly regulated by the oncogenic HOXA9 protein in high-risk pediatric leukemias. The study found two major targets, FLT3 and CDK6, which can be therapeutically targeted with drugs, showing promising outcomes in preclinical models. Additionally, researchers discover...
Researchers at Goethe University Frankfurt have identified a specific gene locus, MYNRL15, that is critical to the survival and replication of leukemia cells. Inhibiting this gene has been shown to deactivate genes necessary for AML cell survival, offering a new possibility for fighting leukemia.
Researchers created a comprehensive chromatin map to understand gene regulatory networks contributing to differences between pediatric acute lymphoblastic leukemia subtypes. The study identified key transcription factor footprints and chromatin accessibility patterns, which can predict leukemia subtype with 89% accuracy.
A study by researchers at the University of Illinois found a significant relationship between soy expansion and childhood leukemia deaths in Brazil. Pesticide use in the region has been linked to increased cancer mortality, with an estimated 123 children under 10 dying from ALL associated with pesticide exposure between 2008 and 2019.
Researchers developed a blood test to detect cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with a high risk of developing cancer. The study provides a proof-of-principle framework for detecting specific cancers earlier, paving the way for further clinical trials and improved patient care.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.